Cargando…

Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis

OBJECTIVES: To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. METHODS: Thirty women with osteoporosis, after denosumab treatment were included. Peri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyrgidis, Athanassios, Yavropoulou, Maria P., Zikos, Petros, Lagoudaki, Roza, Tilaveridis, Jannis, Zouloumis, Lambros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Musculoskeletal and Neuronal Interactions 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493451/
https://www.ncbi.nlm.nih.gov/pubmed/32877971
_version_ 1783582571078090752
author Kyrgidis, Athanassios
Yavropoulou, Maria P.
Zikos, Petros
Lagoudaki, Roza
Tilaveridis, Jannis
Zouloumis, Lambros
author_facet Kyrgidis, Athanassios
Yavropoulou, Maria P.
Zikos, Petros
Lagoudaki, Roza
Tilaveridis, Jannis
Zouloumis, Lambros
author_sort Kyrgidis, Athanassios
collection PubMed
description OBJECTIVES: To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. METHODS: Thirty women with osteoporosis, after denosumab treatment were included. Peripheral blood samples were obtained prior to and 48-72 hours following denosumab administration. Flow cytometry gated at the monocyte population for CD14/CD23/CD123/CD16 stainings were performed. RESULTS: We were able to record a number of changes in the monocyte populations between baseline and after denosumab administration. Most importantly, in the monocyte populations we were able to detect statistically significant increased populations of CD14+/CD23+ (p=0.044), CD14-/CD23+ (p=0.044), CD14+/CD123+ (p=0.011), CD14+/CD123- (p=0.011) and CD14-/CD16+ (p=0.028). In contrast, statistically significant decreased populations of CD14-/CD123+ (p=0.034), CD14+/CD16+ (p=0.037) and CD14+/CD16- (p=0.014) were detected. CONCLUSIONS: Our results provide evidence supporting the hypothesis that denosumab administration modifies the monocyte mediated immune response in a manner similar to that of bisphosphonates. This may partly explain the trivial immunity changes recorded with denosumab.
format Online
Article
Text
id pubmed-7493451
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Society of Musculoskeletal and Neuronal Interactions
record_format MEDLINE/PubMed
spelling pubmed-74934512020-09-21 Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis Kyrgidis, Athanassios Yavropoulou, Maria P. Zikos, Petros Lagoudaki, Roza Tilaveridis, Jannis Zouloumis, Lambros J Musculoskelet Neuronal Interact Original Article OBJECTIVES: To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw. METHODS: Thirty women with osteoporosis, after denosumab treatment were included. Peripheral blood samples were obtained prior to and 48-72 hours following denosumab administration. Flow cytometry gated at the monocyte population for CD14/CD23/CD123/CD16 stainings were performed. RESULTS: We were able to record a number of changes in the monocyte populations between baseline and after denosumab administration. Most importantly, in the monocyte populations we were able to detect statistically significant increased populations of CD14+/CD23+ (p=0.044), CD14-/CD23+ (p=0.044), CD14+/CD123+ (p=0.011), CD14+/CD123- (p=0.011) and CD14-/CD16+ (p=0.028). In contrast, statistically significant decreased populations of CD14-/CD123+ (p=0.034), CD14+/CD16+ (p=0.037) and CD14+/CD16- (p=0.014) were detected. CONCLUSIONS: Our results provide evidence supporting the hypothesis that denosumab administration modifies the monocyte mediated immune response in a manner similar to that of bisphosphonates. This may partly explain the trivial immunity changes recorded with denosumab. International Society of Musculoskeletal and Neuronal Interactions 2020 /pmc/articles/PMC7493451/ /pubmed/32877971 Text en Copyright: © Journal of Musculoskeletal and Neuronal Interactions http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kyrgidis, Athanassios
Yavropoulou, Maria P.
Zikos, Petros
Lagoudaki, Roza
Tilaveridis, Jannis
Zouloumis, Lambros
Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
title Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
title_full Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
title_fullStr Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
title_full_unstemmed Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
title_short Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
title_sort changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493451/
https://www.ncbi.nlm.nih.gov/pubmed/32877971
work_keys_str_mv AT kyrgidisathanassios changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis
AT yavropouloumariap changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis
AT zikospetros changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis
AT lagoudakiroza changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis
AT tilaveridisjannis changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis
AT zouloumislambros changesinperipheralmonocytepopulations4872hoursaftersubcutaneousdenosumabadministrationinwomenwithosteoporosis